Loading
A phase 2 trial of durvalumab and pemigatinib in gallbladder cancer and other biliary tract cancers, run by Mehmet Akce, now recruiting.
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT06728410 by Mehmet Akce, with a registry enrolment figure of 38 participants, started 2026-01-27 and due to reach its primary completion in 2027-07. Interventions recorded: Pemigatinib, Durvalumab. Conditions listed: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation. Gallbladder cancer is named in the registry entry: "5. Histologically diagnosed locally advanced unresectable or metastatic intrahepatic cholangiocarcinoma with FGFR-2 fusion or rearrangement detected by Clinical Laboratory Improvement Act (CLIA)-certified assays includin". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Pemigatinib, Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab and the tag gallbladder-deep-dive.
Shares Pemigatinib, Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
Shares Pemigatinib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Ampullary cancer (ampulla of Vater), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.